FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

作     者：Ran Li Kai Xue Junmin Li Ran Li;Kai Xue;Junmin Li

作者机构：Shanghai Institute of HematologyState Key Laboratory of Medical GenomicsNational Research Center for Translational Medicine at ShanghaiRuijin HospitalShanghai Jiao Tong University School of MedicineShanghai200025China 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2022年第16卷第6期

页      面：896-908页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Key Research and Development Program of China(No.2019YFA0905900) 

主　　题：acute myeloid leukemia FGF13 prognosis immune-related genes bone marrow niches 

摘      要：Fibroblast growth factor 13(FGF13)is aberrantly expressed in multiple cancer types,suggesting its essential role in ***,we aimed to explore its definite role in the development of acute myeloid leukemia(AML)and emphasize its associations with bone marrow *** showed that FGF13 was lowly expressed in patients with AML and that its elevated expression was related to prolonged overall survival(OS).Univariate and multivariate Cox regression analyses identified FGF13 as an independent prognostic factor.A prognostic nomogram integrating FGF13 and clinicopathologic variables was constructed to predict 1-,3-,and 5-year *** mutation and functional analyses indicated that FGF13 was not associated with AML driver mutations but was related to bone marrow *** for immunity,FGF13 was remarkably associated with T cell count,immune checkpoint genes,and *** addition,FGF13 overexpression substantially inhibited the growth and significantly induced the early apoptosis of AML *** xenograft study indicated that FGF13 overexpression prolonged the survival of recipient ***,FGF13 could serve as an independent prognostic factor for AML,and it was closely related to the bone marrow microenvironment.